783 related articles for article (PubMed ID: 19620247)
41. Effect of severe short-term malnutrition on diaphragm muscle signal transduction pathways influencing protein turnover.
Lewis MI; Bodine SC; Kamangar N; Xu X; Da X; Fournier M
J Appl Physiol (1985); 2006 Jun; 100(6):1799-806. PubMed ID: 16484360
[TBL] [Abstract][Full Text] [Related]
42. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
43. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
45. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract][Full Text] [Related]
46. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
47. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
48. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
[TBL] [Abstract][Full Text] [Related]
49. Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the Raf/MEK/ERK and phosphatidylinositol 3-kinase pathways.
Origanti S; Shantz LM
Cancer Res; 2007 May; 67(10):4834-42. PubMed ID: 17510413
[TBL] [Abstract][Full Text] [Related]
50. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
51. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells.
Park JH; Kim JJ; Bae YS
Biochem Biophys Res Commun; 2013 Apr; 433(4):420-5. PubMed ID: 23523798
[TBL] [Abstract][Full Text] [Related]
52. SYK regulates mTOR signaling in AML.
Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
[TBL] [Abstract][Full Text] [Related]
53. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.
von Gise A; Lorenz P; Wellbrock C; Hemmings B; Berberich-Siebelt F; Rapp UR; Troppmair J
Mol Cell Biol; 2001 Apr; 21(7):2324-36. PubMed ID: 11259582
[TBL] [Abstract][Full Text] [Related]
54. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
Wang Q; Zhang X; Song X; Zhang L
Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
[TBL] [Abstract][Full Text] [Related]
56. Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells.
Romano D; Pertuit M; Rasolonjanahary R; Barnier JV; Magalon K; Enjalbert A; Gerard C
Endocrinology; 2006 Dec; 147(12):6036-45. PubMed ID: 16935846
[TBL] [Abstract][Full Text] [Related]
57. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
58. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
59. Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.
Aziz N; Cherwinski H; McMahon M
Mol Cell Biol; 1999 Feb; 19(2):1101-15. PubMed ID: 9891045
[TBL] [Abstract][Full Text] [Related]
60. The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK.
Huang J; Che MI; Lin NY; Hung JS; Huang YT; Lin WC; Huang HC; Lee PH; Liang JT; Huang MC
Mol Carcinog; 2014 Feb; 53 Suppl 1():E62-71. PubMed ID: 23390052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
